| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Juan Carlos Ferrer García, Carlos Sánchez Juan, Agustín Herrera Balleste. Contribution of positron emission tomography to the diagnosis of a case of acromegaly. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion. vol 55. issue 4. 2013-07-25. PMID:22975454. |
diagnosis of acromegaly is based on biochemical tests demonstrating increased growth hormone (gh) secretion. |
2013-07-25 |
2023-08-12 |
Not clear |
| Marek Ruchała, Ewelina Szczepanek-Parulska, Maciej Fularz, Kosma Wolińsk. Risk of neoplasms in acromegaly. Contemporary oncology (Poznan, Poland). vol 16. issue 2. 2013-06-24. PMID:23788865. |
acromegaly is a chronic disease caused by the excessive secretion of growth hormone (gh), and as a result, of insulin-like growth factor-1 (igf-1). |
2013-06-24 |
2023-08-12 |
Not clear |
| Erkan Caglar, Esra Hatipoglu, Mutlu Niyazoglu, Ozlem Celik, Murat Tuncer, Pinar Kadiogl. Acromegaly is not associated with irritable bowel syndrome: a pilot study. Neuro endocrinology letters. vol 34. issue 1. 2013-06-20. PMID:23524627. |
in acromegaly, the gastrointestinal system is under the influence of excessive growth hormone (gh) and insulin like growth factor-1 (igf-i). |
2013-06-20 |
2023-08-12 |
Not clear |
| Pauline Brummelman, Janneke Koerts, Robin P F Dullaart, Gerrit van den Berg, Oliver Tucha, Bruce H R Wolffenbuttel, André P van Bee. Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition. European journal of clinical investigation. vol 42. issue 12. 2013-05-21. PMID:23083406. |
in untreated acromegaly patients, decreased cognitive functioning is reported to be associated with the degree of growth hormone (gh) and igf-1 excess. |
2013-05-21 |
2023-08-12 |
Not clear |
| Pauline Brummelman, Janneke Koerts, Robin P F Dullaart, Gerrit van den Berg, Oliver Tucha, Bruce H R Wolffenbuttel, André P van Bee. Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition. European journal of clinical investigation. vol 42. issue 12. 2013-05-21. PMID:23083406. |
whether previous gh excess or current medical treatment for acromegaly specifically affects cognition remains unclear. |
2013-05-21 |
2023-08-12 |
Not clear |
| Brian N Kelly, Doris M Haverstick, Mary Lee Vance, Michael O Thorner, David E Brun. Quantification of growth hormone mRNA in blood. Clinica chimica acta; international journal of clinical chemistry. vol 414. 2013-05-17. PMID:22985689. |
growth hormone (gh) is present in human lymphocytes and the relative concentration of gh mrna in circulating cells is reportedly increased in patients with acromegaly. |
2013-05-17 |
2023-08-12 |
human |
| Laura Boero, Marcos Manavela, Karina Danilowicz, Analia Alfieri, Maria Carolina Ballarino, Alberto Chervin, Natalia García-Basavilbaso, Mariela Glerean, Mirtha Guitelman, Monica Graciela Loto, Jose Alberto Nahmías, Amelia Susana Rogozinski, Marisa Servidio, Nicolas Marcelo Vitale, Débora Katz, Patricia Fainstein Day, Graciela Stalldecker, Maria Susana Mallea-Gi. Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients. Pituitary. vol 15. issue 4. 2013-05-07. PMID:21960211. |
in conclusion, discrepant gh and igf-i levels in the diagnosis and follow-up of patients with acromegaly requires consideration of many factors that influence these parameters. |
2013-05-07 |
2023-08-12 |
Not clear |
| Federica Guaraldi, Patrizio Caturegli, Roberto Salvator. Prevalence of antipituitary antibodies in acromegaly. Pituitary. vol 15. issue 4. 2013-05-07. PMID:22002711. |
acromegaly is a rare disorder due to an excessive production of growth hormone (gh), typically caused by a gh-secreting pituitary adenoma. |
2013-05-07 |
2023-08-12 |
human |
| Jessica A Brzana, Chris G Yedinak, Johnny B Delashaw, Hume S Gultelkin, David Cook, Maria Fleseri. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary. vol 15. issue 4. 2013-05-07. PMID:22183781. |
discordant growth hormone and igf-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, gh or igf-1 values? |
2013-05-07 |
2023-08-12 |
Not clear |
| Jessica A Brzana, Chris G Yedinak, Johnny B Delashaw, Hume S Gultelkin, David Cook, Maria Fleseri. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary. vol 15. issue 4. 2013-05-07. PMID:22183781. |
new criteria that define acromegaly remission are more stringent: normal (age/sex-adjusted) insulin-like growth factor type 1 (igf-1), growth hormone (gh) random (ghr) <1 μg/l, and a gh nadir (ghn) during oral glucose tolerance test (ogtt) of <0.4 μg/l. |
2013-05-07 |
2023-08-12 |
Not clear |
| Jessica A Brzana, Chris G Yedinak, Johnny B Delashaw, Hume S Gultelkin, David Cook, Maria Fleseri. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary. vol 15. issue 4. 2013-05-07. PMID:22183781. |
we retrospectively analyzed data over a 5 year time period (2006-2010), in post-surgery acromegaly patients who had elevated igf-1 but normal gh levels (per the new cure criteria). |
2013-05-07 |
2023-08-12 |
Not clear |
| Jessica A Brzana, Chris G Yedinak, Johnny B Delashaw, Hume S Gultelkin, David Cook, Maria Fleseri. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary. vol 15. issue 4. 2013-05-07. PMID:22183781. |
in our study of postoperative patients with acromegaly naïve to both srls and radiation, using new gh cut-off levels, 24% had intermittent or persistent discordant values. |
2013-05-07 |
2023-08-12 |
Not clear |
| Jessica A Brzana, Chris G Yedinak, Johnny B Delashaw, Hume S Gultelkin, David Cook, Maria Fleseri. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary. vol 15. issue 4. 2013-05-07. PMID:22183781. |
our results highlight that relying on igf-1 or gh measurements alone is not adequate for assessing disease control in surgically treated acromegaly patients. |
2013-05-07 |
2023-08-12 |
Not clear |
| Anand K Annamalai, Alison Webb, Narayanan Kandasamy, Maysoon Elkhawad, Samantha Moir, Fakhar Khan, Kaisa Maki-Petaja, Emma L Gayton, Christopher H Strey, Samuel O'Toole, Shaumya Ariyaratnam, David J Halsall, Afzal N Chaudhry, Laurence Berman, Daniel J Scoffings, Nagui M Antoun, David P Dutka, Ian B Wilkinson, John M Shneerson, John D Pickard, Helen L Simpson, Mark Gurnel. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. The Journal of clinical endocrinology and metabolism. vol 98. issue 3. 2013-04-30. PMID:23393175. |
attainment of safe gh and igf-1 levels is a central goal of acromegaly management. |
2013-04-30 |
2023-08-12 |
Not clear |
| V Gasco, G Beccuti, F Marotta, N Prencipe, M Maccario, J Janssen, A J van der Lely, E Ghigo, S Grottol. Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients. Journal of endocrinological investigation. vol 35. issue 4. 2013-04-02. PMID:21642764. |
ss analogues in acromegaly reduce total igf-i levels inhibiting gh hypersecretion, but they also reduce free igf-i bioactivity increasing igfbp-1 levels by inducing insulin decrease. |
2013-04-02 |
2023-08-12 |
Not clear |
| Fumiko Yokota, Hiroshi Arima, Miho Hirano, Tomohiro Uchikawa, Yasuya Inden, Tetsuya Nagatani, Yutaka Ois. Normalisation of plasma growth hormone levels improved cardiac dysfunction due to acromegalic cardiomyopathy with severe fibrosis. BMJ case reports. vol 2010. 2013-03-22. PMID:22791498. |
the current case demonstrates that cardiac dysfunction in acromegaly could be recovered by normalisation of gh and igf-1 even in the presence of severe fibrosis in the myocardium. |
2013-03-22 |
2023-08-12 |
Not clear |
| Yves Le Bouc, Frédéric Brioud. [Is there a relationship between the growth hormone dose and tumoral or cardiovascular complications?]. Bulletin de l'Academie nationale de medecine. vol 196. issue 1. 2013-03-12. PMID:23259340. |
however, it has been reported that cancers and cardiovascular diseases are associated with high plasma concentrations of gh and igf1, particularly in patients with acromegaly but also in large epidemiological studies of apparently healthy populations. |
2013-03-12 |
2023-08-12 |
Not clear |
| M Galdiero, R Pivonello, L F S Grasso, A Cozzolino, A Cola. Growth hormone, prolactin, and sexuality. Journal of endocrinological investigation. vol 35. issue 8. 2013-03-07. PMID:23014134. |
sexual function in men and women with gh deficiency (ghd) and gh excess, particularly in acromegaly, is scantily studied and gh- or igf-i-dependent effects are difficult to quantify. |
2013-03-07 |
2023-08-12 |
Not clear |
| M Galdiero, R Pivonello, L F S Grasso, A Cozzolino, A Cola. Growth hormone, prolactin, and sexuality. Journal of endocrinological investigation. vol 35. issue 8. 2013-03-07. PMID:23014134. |
data on beneficial effects of gh replacement therapy and specific surgical or pharmacological approach for acromegaly are far to be fully elucidated although restoring normal gh/igf-i levels have been associated to improvement of sexual function. |
2013-03-07 |
2023-08-12 |
Not clear |
| Rajat Kumar Das, Sarmistha Banerjee, Bernard H Shapir. Noncanonical suppression of GH-dependent isoforms of cytochrome P450 by the somatostatin analog octreotide. The Journal of endocrinology. vol 216. issue 1. 2013-03-01. PMID:23077183. |
octreotide is a potent somatostatin analog therapeutically used to treat several conditions including hyper gh secretion in patients with acromegaly. |
2013-03-01 |
2023-08-12 |
human |